third
articl
year
review
report
public
intens
care
sever
infect
includ
endocard
periton
septic
shock
healthcar
ventil
associ
pneumonia
highli
resist
bacteria
antimicrobi
therapi
includ
antibiot
stewardship
therapeut
drug
monitor
deescal
invas
fungal
infect
sever
viral
infect
ebola
viru
diseas
paediatr
circulatori
dysfunct
frequent
present
patient
admit
icu
literatur
diagnos
treatment
monitor
shock
updat
frequent
import
uptod
guidelin
import
process
facilit
establish
nationalloc
guidelin
product
consensu
statement
scientif
societi
therefor
european
societi
intens
care
medicin
form
taskforc
review
literatur
expert
opinion
diagnosi
treatment
monitor
circulatori
shock
report
long
expect
updat
public
intern
consensu
confer
hemodynam
monitor
shock
taskforc
produc
statement
use
grade
system
principl
includ
studi
publish
octob
therefor
consensu
statement
publish
decemb
issu
intens
care
medicin
repres
uptod
view
current
evid
taskforc
recommend
use
current
recommend
preload
paramet
sole
target
fluid
resuscit
target
ventricular
fill
pressur
volum
taskforc
recommend
fluid
resuscit
patient
use
one
singl
hemodynam
variabl
use
dynam
instead
static
variabl
predict
fluid
respons
whenev
possibl
sharp
contrast
recent
publish
guidelin
treatment
sepsi
septic
shock
surviv
sepsi
campaign
ssc
addit
guid
fluid
resuscit
cvp
might
even
prove
harm
nevertheless
use
ssc
guidelin
report
improv
surviv
sever
sepsi
septic
shock
adher
resuscit
manag
bundl
guidelin
associ
improv
surviv
particip
individu
site
ssc
result
signific
drop
hospit
mortal
everi
month
increas
site
complianc
resuscit
bundl
significantli
improv
icu
hospit
length
stay
context
previou
part
question
aris
whether
import
clinic
effect
sscguidelin
result
adequaci
target
guidelin
effect
protocol
standard
care
like
combin
effect
warrant
optim
sscguidelin
rather
discard
adequaci
fluid
resuscit
everi
kind
circulatori
failur
depend
good
understand
physiolog
circul
three
public
contribut
import
aspect
two
public
focus
understand
venou
return
hypovolaemia
two
topic
close
link
therapi
hypovolaemia
increas
venou
return
use
cvp
context
would
assess
whether
heart
effici
handl
increas
venou
return
rather
use
increas
cvp
indic
adequ
increas
venou
return
challeng
circulatori
failur
septic
shock
aspect
three
pillar
circul
vasculatur
volum
heart
might
affect
understand
pathophysiolog
cardiac
failur
import
like
affect
treatment
import
realiz
circul
volum
equal
total
blood
volum
mistak
frequent
made
junior
doctor
nurs
compens
state
hypovolemia
total
blood
volum
sum
stress
unstress
volum
decreas
stress
volum
maintain
therefor
cardiac
output
may
maintain
well
result
increas
activ
sympathet
nervou
system
translat
clinic
practic
decreas
peripher
perfus
import
marker
decreas
peripher
perfus
prolong
capillari
refil
time
mani
studi
shown
abnorm
peripher
perfus
import
warn
sign
critic
ill
patient
whether
abnorm
skin
color
abnorm
tissu
hemoglobin
satur
increas
capillari
refil
time
abnorm
peripher
tissu
perfus
correct
specif
therapi
next
logic
step
would
incorpor
use
peripher
perfus
paramet
specif
treatment
diagnost
therapeut
protocol
defin
efficaci
use
paramet
although
mani
techniqu
avail
assess
state
circul
echo
cardiographi
gain
import
last
year
taskforc
esicm
recommend
use
echocardiographi
prefer
modal
patient
clinic
examin
fail
determin
type
shock
addit
echocardiographi
noninvas
techniqu
sequenti
evalu
cardiac
function
patient
circulatori
failur
thu
prefer
routin
use
pulmonari
arteri
cathet
mechan
ventil
critic
ill
patient
use
lung
ultrasound
significantli
chang
clinic
decis
therapeut
manag
studi
patient
therapi
chang
directli
patient
patient
combin
lung
ultrasound
echocardiographi
proven
superior
use
lung
ultrasound
therefor
thorac
echocardiographi
import
compet
current
curriculum
traine
intens
care
role
hypothalamicpituitaryadren
axi
hpa
critic
ill
patient
remain
subject
interest
discuss
support
axi
use
hydrocortison
vasopressin
remain
actual
hpa
hormon
seem
relat
sever
diseas
earli
sepsi
progress
septic
shock
although
hydrocortison
vasopressor
spare
effect
nt
seem
affect
vasopressin
level
mortal
role
thu
need
clarif
recommend
combin
treatment
made
also
discuss
use
vasopressin
hormon
substitut
vasopressor
need
clarif
use
vasopressor
associ
seriou
advers
event
relat
vasopressin
blood
level
presenc
specif
genotyp
interact
immun
system
infecti
organ
fulli
understood
recent
new
articl
dougla
et
al
emphas
role
innat
respons
sepsi
inde
innatelik
lymphocyt
recent
describ
subset
immun
respons
known
antibacteri
properti
human
trial
critic
ill
patient
provid
first
evid
drop
mait
cell
bacteri
sepsi
compound
alreadi
known
immun
defect
persist
deplet
potenti
nosocomi
infect
interest
find
like
provid
fertil
ground
futur
studi
well
recogn
earli
appropri
antimicrobi
therapi
reduc
infectionrel
morbid
mortal
critic
ill
patient
import
pharmacodynam
pd
dose
optim
drug
exposur
continu
evolv
sinc
well
recogn
betalactam
efficaci
driven
time
drug
concentr
exce
mic
mic
target
pathogen
mani
strategi
focus
alter
infus
time
clinic
set
betalactam
optim
strategi
often
includ
use
prolong
infus
ie
dose
administ
h
dose
interv
continu
infus
total
daili
dose
given
constant
rate
h
strategi
report
enhanc
efficaci
compar
convent
regimen
report
bassetti
et
al
editori
interest
intrigu
studi
de
wael
et
al
use
dali
studi
prospect
multicentr
pharmacokinet
pointpreval
studi
shown
critic
ill
patient
receiv
differ
blactam
antibiot
antibiot
free
drug
concentr
remain
mic
dose
interv
patient
respect
use
intermitt
infus
significantli
associ
increas
risk
nonattain
target
creatinin
clearanc
independ
associ
reach
free
time
mic
ft
mic
target
studi
demonstr
simul
empir
set
broad
rang
pathogen
suscept
breakpoint
target
target
attain
use
convent
blactam
antibiot
dose
gener
inadequ
although
sever
factor
play
role
use
intermitt
infus
result
three
four
fold
increas
likelihood
reach
desir
pkpd
target
anoth
studi
de
wael
et
al
prospect
analyz
effect
dose
adapt
strategi
use
daili
therapeut
drug
monitor
tdm
target
attain
meropenem
piperacillintazobactam
pneumonia
primari
infecti
diagnosi
fortyon
patient
includ
studi
eightyf
percent
patient
tdm
group
need
dose
adapt
requir
addit
increas
h
target
attain
rate
ft
ft
mic
higher
tdm
group
vs
p
vs
p
respect
studi
support
strategi
dose
adapt
base
daili
therapeut
drug
monitor
lead
increas
pkpd
target
attain
compar
convent
dose
critic
ill
patient
normal
kidney
function
aminoglycosid
continu
essenti
antibiot
icu
aminoglycosid
use
critic
ill
patient
crucial
efficaci
maxim
aminoglycosid
concentr
depend
antibiot
peak
concentr
mic
relev
pk
pd
paramet
studi
shown
aminoglycosid
maxim
effect
c
max
mic
ratio
mean
tdm
efficaci
may
help
guid
therapi
base
consider
well
decreas
suscept
microorgan
actual
pkguid
dose
base
individu
plasma
concentr
prefer
critic
ill
patient
initi
therapi
mic
known
use
higher
dose
amikacin
mgkg
gentamycin
mgkg
tobramycin
mgkg
compens
chang
describ
c
max
previou
dose
guid
subsequ
dose
report
dimopoulo
editori
context
recent
studi
shed
light
aminoglycosid
pkpd
properti
icu
patient
prospect
studi
conduct
de
montmollin
et
al
gener
icu
patient
receiv
load
dose
amikacin
mgkg
total
bodi
weight
tbw
still
amikacin
c
max
mg
l
posit
fluid
balanc
identifi
predict
factor
c
max
mgl
low
bmi
tend
associ
amikacin
underdos
tbw
use
suggest
need
higher
dose
patient
posit
fluid
balanc
whether
regimen
associ
improv
outcom
unknown
therefor
prospect
random
control
studi
warrant
assess
effect
higher
load
dose
amikacin
c
max
infect
control
surviv
impact
renal
hear
function
compound
tigecyclin
extens
studi
potenti
activ
extens
drugresist
bacteria
us
food
drug
administr
fda
report
increas
risk
mortal
associ
tigecyclin
use
comparison
drug
treatment
seriou
infect
analysi
use
pool
group
random
clinic
trial
includ
hospitalacquir
pneumonia
hap
ventilatorassoci
pneumonia
vap
complic
skin
soft
tissu
infect
cssti
complic
intraabdomin
infect
ciai
diabet
foot
infect
basi
pool
data
analysi
fda
recommend
altern
tigecyclin
consid
patient
sever
infect
interest
articl
montrav
et
al
conclud
tigecyclin
success
rate
patient
icu
sever
infect
appear
compar
report
antibiot
overal
success
rate
end
treatment
day
later
furthermor
report
surviv
rate
day
histor
clinic
trial
concern
manag
critic
ill
particularli
icuadmit
patient
tigecyclin
limit
despit
obscur
vision
provid
impress
number
metaanalys
tigecyclin
expect
use
often
approv
indic
offlabel
combin
regimen
treatment
mdr
gramneg
infect
routin
clinic
practic
greatli
support
montrav
studi
mention
increas
medic
need
repres
grow
impact
multiresist
infect
current
lack
altern
new
antibiot
suggest
tigecyclin
benefitrisk
continu
posit
anoth
way
save
antimicrobi
deescal
often
possibl
mani
import
paper
publish
journal
field
antimicrobi
deescal
clinic
approach
empir
antibiot
treatment
seriou
infect
attempt
balanc
need
appropri
initi
therapi
need
limit
unnecessari
antimicrobi
exposur
order
curtail
emerg
resist
although
concept
antimicrobi
deescal
seem
make
intuit
sens
clinician
ask
realist
expect
strategi
intensivist
expect
deescal
approach
antimicrobi
therapi
critic
ill
patient
optim
patient
outcom
said
dr
kollef
editori
interest
complet
studi
garnachomontero
et
al
evalu
patient
sever
sepsi
septic
shock
icu
admiss
treat
empir
broadspectrum
antibiot
antibiot
therapi
guid
written
protocol
advoc
deescal
therapi
microbiolog
result
becam
avail
day
cultur
result
although
decis
ultim
respons
physician
charg
patient
multivari
analysi
factor
independ
associ
inhospit
mortal
septic
shock
sofa
score
day
cultur
result
inappropri
empir
antimicrobi
therapi
wherea
deescal
antimicrobi
therapi
found
protect
factor
hospit
surviv
addit
among
patient
receiv
appropri
therapi
factor
independ
associ
mortal
sofa
score
day
cultur
result
wherea
deescal
therapi
found
protect
factor
set
neutropen
patient
sever
sepsi
septic
shock
use
broadspectrum
antibiot
recommend
date
first
studi
safeti
deescal
neutropen
patient
publish
journal
mokart
et
al
deescal
antimicrobi
therapi
consist
either
delet
one
empir
antibiot
combin
treatment
whenev
possibl
use
betalactam
antibiot
narrow
spectrum
activ
cumul
incid
deescal
empir
antimicrobi
treatment
among
patient
cohort
confid
interv
ci
includ
patient
ongo
neutropenia
microbiolog
document
avail
patient
deescal
significantli
modifi
hazard
death
within
first
hr
ci
within
year
icudischarg
hr
ci
result
studi
encourag
impress
first
time
author
shown
icu
deescal
frequent
perform
neutropen
cancer
patient
sever
sepsi
approach
appear
affect
outcom
surpris
appar
expect
result
deescal
therapi
shown
leon
et
al
multicent
nonblind
random
noninferior
trial
includ
patient
sever
sepsi
randomli
assign
deescal
continu
empir
antimicrobi
treatment
result
shown
median
durat
icu
stay
interquartil
rang
iqr
day
deescal
group
iqr
day
continu
group
respect
p
mean
differ
ci
superinfect
occur
patient
deescal
group
six
patient
continu
group
p
number
antibiot
day
deescal
group
continu
group
respect
p
mortal
similar
group
current
studi
cast
signific
doubt
whether
reduct
spectrum
antibiot
consid
safe
routin
measur
author
demonstr
deescal
defin
narrow
spectrum
antibiot
inferior
continu
initi
antibiot
therapi
length
stay
primari
outcom
paramet
furthermor
antibiot
use
higher
deescal
group
presum
driven
number
superinfect
deescal
group
key
element
studi
potenti
role
deescal
uniform
definit
deescal
deescalationdefin
narrow
spectrum
antibiot
treatmentshould
cautious
appli
base
particular
patient
clinic
statu
consid
icu
environ
whole
et
al
prospect
compar
epidemiolog
antibiot
therapi
clinic
outcom
patient
commun
acquir
pneumonia
cap
health
care
acquir
pneumonia
hcap
immunocompromis
patient
icp
pneumonia
admit
spanish
icu
year
period
found
hcap
patient
comorbid
wors
clinic
statu
compar
two
subgroup
hcap
icp
often
need
mechan
ventil
often
underw
tracheostomi
incid
gramneg
pathogen
mrsa
pseudomona
aeruginosa
low
overal
higher
hcap
icp
inappropri
empir
antibiot
therapi
cap
hcap
icp
mortal
highest
icp
differ
cap
hcap
author
conclud
empir
antibiot
regimen
recommend
cap
would
appropri
patient
hcap
consequ
systemat
cover
multidrugresist
pathogen
hcap
necessari
diagnosi
ventilatorassoci
pneumonia
vap
problem
yet
fulli
solv
fact
major
advanc
sinc
last
metaanalysi
publish
cochran
collabor
real
major
advanc
come
rapid
pcr
pointofcar
techniqu
result
yet
avail
bo
et
al
publish
articl
new
intens
care
section
potenti
innov
could
improv
earli
recognit
vap
author
suggest
new
techniqu
promis
detect
airway
colon
pulmonari
infect
earli
phase
first
techniqu
would
use
colorimetr
assay
insid
endotrach
tube
detect
type
bacteria
pattern
resist
second
techniqu
base
detect
volatil
compound
hydrocarbon
alcohol
aldehyd
keton
sulfidecontain
molecul
releas
bacteria
caus
vap
techniqu
still
earli
clinic
phase
need
valid
postop
nosocomi
pneumonia
threaten
complic
major
surgeri
cardiovascular
thorac
abdomin
high
morbid
mortal
improv
help
prevent
postop
pneumonia
welcom
preoper
oral
care
nonstandard
prophylact
measur
bergan
et
al
perform
prospect
studi
implement
sever
oralhygien
measur
includ
dentist
visit
brush
teeth
tongu
oral
rins
chlorhexidin
twice
day
surgeri
measur
abl
reduc
pneumonia
incid
rate
case
ventil
day
month
period
studi
case
per
day
mechan
ventil
month
follow
studi
oral
chlorhexidin
rins
preoper
period
day
surgeri
significantli
significantli
protect
postop
pneumonia
oral
chlorhexidin
rins
dental
hygien
cheap
easi
effect
measur
prevent
pneumonia
cardiac
surgeri
colon
better
indic
bacteri
dynam
infect
sinc
colon
lead
infect
small
group
contribut
significantli
epidemiolog
bacteria
knowledg
time
clearanc
resist
bacteria
great
import
understand
nosocomi
dynam
predict
effect
intervent
studi
haverk
et
al
studi
patient
screen
admiss
twice
weekli
resist
bacteria
icu
european
countri
mosaricu
trial
uniqu
patient
episod
colon
least
one
readmiss
thirtytwo
patient
colon
two
resist
bacteria
median
time
clearanc
month
resist
strain
month
highli
resist
enterobacteriacea
less
month
mrsa
month
vancomycin
resist
enterococci
antimicrobialresist
bacteri
speci
patient
lost
colon
readmit
two
month
previou
icu
admiss
although
studi
perform
select
hospit
patient
ie
patient
admit
icu
result
critic
import
sinc
patient
especi
prone
colon
subsequ
infect
bacteremia
one
major
caus
nosocomi
infect
intens
care
unit
icu
icuacquir
bloodstream
infect
icubsi
associ
increas
morbid
length
stay
result
excess
cost
high
mortal
critic
ill
patient
although
variat
due
heterogen
inform
sourc
varieti
local
clinic
practic
coagulaseneg
staphylococci
staphylococcu
aureu
enterobacteriacea
speci
pathogen
frequent
respons
nosocomi
bacteremia
energi
deficit
icu
patient
mainli
caus
reduc
intak
due
underprescrib
calori
frequent
feed
interrupt
cumul
energi
deficit
buildup
first
day
icu
stay
appear
independ
factor
contribut
nosocomi
infect
interest
studi
ekp
et
al
investig
impact
energi
deficit
microbiolog
result
blood
cultur
prolong
acut
mechan
ventil
patient
experienc
first
icubsi
episod
daili
energi
balanc
compar
accord
microbiolog
result
blood
cultur
consecut
prolong
h
acut
mechan
ventil
patient
develop
first
episod
icubsi
among
icubsi
due
methicillinresist
staphylococcu
aureu
mrsa
cumul
energi
deficit
patient
mrsa
icubsi
greater
icubsi
caus
pathogen
icu
admiss
risk
factor
nosocomi
infect
nutrit
statu
condit
potenti
limit
feed
differ
significantli
two
group
patient
mrsa
icubsi
lower
deliv
energi
similar
energi
expenditur
caus
higher
energi
deficit
sever
energi
deficit
higher
rate
mrsa
blood
cultur
p
compar
quartil
observ
conclus
studi
earli
inicu
energi
deficit
associ
mrsa
icubsi
prolong
acut
mechan
ventil
patient
result
suggest
limit
earli
energi
deficit
could
way
optim
mrsa
icubsi
prevent
bacteremia
import
caus
mortal
prolong
stay
excess
healthcar
cost
even
paediatr
intens
care
unit
picu
estim
bsi
occur
picu
thought
relat
use
central
venou
cathet
cvc
adher
full
steril
procedur
may
compromis
cvc
insert
part
emerg
resuscit
stabilis
particularli
outsid
intens
care
unit
half
emerg
admiss
picu
uk
occur
stabilis
hospit
studi
harron
et
al
made
uk
determin
whether
bloodstream
infect
bsi
occur
frequent
children
admit
picu
interhospit
transfer
compar
within
hospit
admiss
multivari
regress
show
signific
differ
rate
picuacquir
bsi
sourc
admiss
incidencer
ratio
interhospit
transfer
versu
withinhospit
admiss
ci
adjust
riskfactor
rate
interhospit
transfer
decreas
rapidli
ci
per
year
compar
ci
per
year
within
hospit
admiss
median
time
first
picuacquir
bsi
differ
significantli
interhospit
transfer
day
iqr
withinhospit
admiss
day
author
conclud
interhospit
transfer
longer
signific
risk
factor
form
picuacquir
bsi
given
larg
proport
infect
occur
second
week
admiss
initi
reduc
picuacquir
bsi
focu
maintain
steril
procedur
admiss
faecal
periton
fp
common
caus
secondari
periton
caus
spillag
faecal
materi
larg
bowel
peritoneum
genet
sepsi
septic
shock
europ
genosept
project
investig
influenc
genet
variat
host
respons
outcom
larg
cohort
patient
sepsi
admit
icu
across
europ
trident
et
al
report
studi
data
fp
patient
admit
center
across
countri
common
caus
fp
perfor
diverticular
diseas
surgic
anastomot
breakdown
icu
mortal
rate
day
increas
month
caus
fp
preexist
comorbid
time
estim
onset
symptom
surgeri
impact
surviv
strongest
independ
risk
factor
associ
increas
rate
death
month
includ
age
higher
apach
ii
score
acut
renal
cardiovascular
dysfunct
within
one
week
admiss
icu
hypothermia
lower
haematocrit
bradycardia
day
icu
stay
although
recent
literatur
plenti
studi
concern
aspect
infect
endocard
ie
focu
sever
ie
requir
admiss
icu
paper
year
later
wolff
et
al
affirm
sinc
public
paper
lot
inform
accumul
manag
ie
set
blood
cultur
allow
identif
case
cultur
neg
ie
still
remain
diagnost
challeng
bloodpolymeras
chain
reaction
valv
tissu
may
yield
microbiolog
diagnosi
new
imag
techniqu
petct
scan
shown
addit
valu
patient
intracardiac
devic
valvular
prosthesi
systemat
cerebr
magnet
reson
imag
lead
modif
therapeut
plan
decis
oper
time
cardiac
surgeri
take
account
presenc
congest
heart
failur
neurolog
complic
renal
failur
multiorgan
dysfunct
syndrom
strongest
independ
predictor
postop
mortal
preoper
multiorgan
failur
score
neurolog
failur
also
repres
major
determin
mortal
regardless
mechan
neurolog
complic
fungal
infect
particular
candida
speci
respons
bloodstream
infect
fourth
common
caus
nosocomi
bloodstream
infect
us
popul
survey
sixth
seventh
common
caus
european
survey
candida
bloodstream
infect
occur
highest
rate
icu
popul
set
account
candidemia
complet
use
review
leon
et
al
describ
high
proport
icu
patient
becom
colon
candida
speci
develop
invas
candidiasi
invas
candidiasi
candidaemia
difficult
predict
earli
diagnosi
remain
major
challeng
addit
microbiolog
document
occur
often
late
cours
infect
delay
initi
appropri
treatment
associ
increas
mortal
attempt
decreas
candidarel
mortal
increas
number
critic
ill
patient
without
document
candida
infect
receiv
empir
system
antifung
therapi
lead
concern
antifung
overus
scorespredict
rule
permit
stratif
select
high
risk
patient
may
benefit
earli
antifung
therapi
howev
far
better
neg
predict
valu
posit
predict
valu
new
biomark
mannan
antimannan
bdglucan
polymeras
chain
reaction
increasingli
use
enabl
earlier
diagnosi
ideal
provid
prognost
inform
andor
therapeut
monitor
although
reason
sensit
specif
techniqu
remain
larg
investig
clinic
use
yet
establish
eleg
studi
lortholari
et
al
report
activ
hospitalbas
surveil
program
incid
episod
candidemia
twentyfour
tertiari
care
hospit
pari
area
among
adult
case
includ
candida
isol
collect
speci
c
albican
c
glabrata
c
parapsilosi
c
tropicali
c
krusei
c
kefyr
candidemia
occur
icu
patient
compar
icu
vs
nonicu
patient
former
significantli
frequent
surgeri
past
day
often
preexpos
fluconazol
treat
echinocandin
less
frequent
infect
c
parapsilosi
signific
increas
incid
overal
popul
icu
found
echinocandin
initi
therapi
increas
time
icu
first
year
studi
period
assess
predictor
mortal
report
mortal
rate
decreas
period
period
p
predictor
mortal
multivari
analysi
older
age
period
receipt
corticosteroid
higher
apach
ii
score
treatment
echinocandin
associ
higher
probabl
surviv
author
conclud
incorpor
echinocandin
primari
therapi
candidemia
seem
associ
better
outcom
bacteri
infect
howev
adequ
treatment
remain
paramount
import
treat
infect
critic
ill
patient
also
patient
candida
blood
stream
infect
inadequ
sourc
control
antifung
treatment
associ
increas
mortal
anoth
import
phenomenon
manag
candida
infect
repres
emerg
resist
candida
spp
antifung
drug
resist
consid
less
problemat
candida
spp
pathogen
recent
increas
resist
echinocandin
azol
led
clinic
failur
extens
review
maubon
et
al
report
acquir
fluconazol
resist
frequent
c
glabrata
increasingli
display
crossresist
voriconazol
far
multidrug
resist
phenotyp
azol
echinocandin
describ
c
glabrata
matter
seriou
concern
fluconazol
resist
remain
uncommon
c
albican
preval
c
parapsilosi
c
tropicali
howev
recent
data
show
may
reflect
geograph
differ
acquir
resist
echinocandin
increasingli
report
clinic
import
candida
spp
remain
uncommon
c
albican
c
tropicali
c
krusei
becom
frequent
c
glabrata
candida
spp
colon
airway
frequent
report
mechan
ventil
critic
ill
patient
clinic
signific
difficult
evalu
candida
low
affin
alveolar
pneumocyt
histolog
document
pneumonia
rare
report
hematogen
dissemin
context
candidemia
may
respons
multipl
pulmonari
abscess
view
distinct
entiti
henc
exist
true
candid
pneumonia
doubt
recoveri
candida
spp
respiratori
tract
gener
consid
colon
justifi
antifung
therapi
doubleblind
placebocontrol
multicent
pilot
random
trial
martin
et
al
tri
demonstr
benefit
antifung
therapi
critic
ill
patient
posit
airway
secret
specimen
candida
spp
recruit
patient
random
trial
patient
specif
treat
antifung
marker
inflamm
clinic
outcom
compar
placebo
antifung
treatment
group
baselin
time
baselin
plasma
tnfalpha
level
higher
patient
colon
candida
compar
observ
group
mean
sd
vs
pgml
p
patient
lower
innat
immun
function
evidenc
reduc
whole
blood
ex
vivo
lpsinduc
tnfalpha
product
capac
vs
pgml
p
studi
provid
evid
support
larger
trial
examin
efficaci
empir
antifung
treatment
patient
candida
endotrach
secret
similar
neg
impact
durat
mechan
ventil
obtain
inhal
amphotericinb
patient
airway
colon
candida
sp
amphob
inhal
therapi
associ
increas
decolon
might
even
prolong
durat
mechan
ventil
possibl
due
toxic
drug
lung
addit
small
random
studi
efficaci
empir
treatment
suspect
ventil
associ
pneumonia
patient
candida
colon
respiratori
tract
prove
effect
studi
persist
inflamm
immunosuppress
associ
candida
colon
lung
respiratori
tract
colon
critic
ill
patient
therefor
remain
import
problem
prevent
fungal
infect
oral
prophylaxi
nystatin
recent
evalu
shown
result
reduct
candida
colon
develop
candida
colon
index
ci
view
major
conceptu
advanc
character
support
progress
colon
infect
surgic
patient
paper
twenti
year
later
eggimann
et
al
affirm
sinc
public
paper
mani
center
use
ci
methodolog
deriv
origin
descript
assess
dynam
candida
colon
differ
subgroup
critic
ill
patient
risk
invas
candidiasi
unfortun
data
valid
larg
multicent
trial
sever
studi
indirectli
suggest
valid
potenti
use
ci
almost
exclus
surgic
patient
among
pitfal
emphas
workintens
limit
bedsid
practic
furthermor
limit
data
avail
nonsurg
patient
cost
effect
use
manag
critic
ill
patient
remain
proven
larg
prospect
clinic
trial
koulenti
et
al
analyz
data
epidemiolog
clinic
aspect
diagnost
novelti
invas
pulmonari
aspergillosi
ipa
icu
patient
conclud
identif
highrisk
profil
ipa
icu
patient
without
appar
immunosuppress
might
help
achiev
earlier
ipa
diagnosi
would
lead
higher
level
suspicion
lower
threshold
perform
thorough
diagnost
workout
patient
highrisk
epidemiolog
research
aim
identifi
highrisk
patient
ipa
go
http
recent
year
antineoplast
treatment
regimen
hematolog
patient
intensifi
led
signific
increas
icu
admiss
due
sever
infecti
complic
among
patient
pulmonari
infiltr
fungal
etiolog
among
common
find
associ
febril
episod
increas
avail
high
resolut
multislic
ct
render
convent
chest
radiograph
less
obsolet
diagnos
lung
infiltr
febril
neutropen
patient
recent
year
viral
communityacquir
pneumonia
cap
report
frequent
microbi
etiolog
sever
cap
due
part
new
diagnost
techniqu
allow
detect
old
new
virus
middl
east
respiratori
syndrom
mer
one
new
viral
diseas
caus
rna
betacoronoraviru
leung
gomersal
describ
intens
care
medicin
epidemiolog
pathogenesi
clinic
featur
diagnosi
treatment
implic
intens
care
manag
clinic
featur
diseas
indistinguish
viral
diseas
includ
viral
pneumon
diagnosi
made
mean
epidemiolog
background
middleeast
travel
plu
examin
blood
urin
stool
conjunctiv
swab
cerebrospin
fluid
sampl
viru
found
use
realtim
reversetranscript
pcr
patient
admit
icu
requir
mechan
ventil
shock
renal
failur
also
frequent
unfortun
specif
antivir
treatment
ebola
viru
one
virul
human
pathogen
sinc
ebola
viru
diseas
evd
caus
outbreak
africa
case
fatal
rate
absenc
approv
treatment
vaccin
transmit
direct
contact
broken
skin
mucou
membran
blood
urin
saliva
fece
vomit
bodi
fluid
symptomat
infect
patient
convalesc
person
contamin
needl
stick
evd
outbreak
west
africa
public
health
emerg
intern
concern
tattevin
et
al
affirm
everi
physician
activ
emerg
depart
icu
worldwid
may
turn
involv
care
patient
suspect
evd
takehom
messag
paper
suspect
evd
patient
present
fever
within
three
week
stay
guinea
sierra
leon
liberia
nigeria
implement
infect
control
procedur
prevent
secondari
case
case
evd
confirm
ensur
plausibl
differenti
diagnos
appropri
consid
manag
even
parkesratanshi
et
al
articl
urgent
recommend
health
facil
consult
nation
guidelin
evd
develop
local
action
plan
epidem
internet
social
media
twitter
effect
use
dissemin
inform
govern
medic
press
predict
end
epidem
far
away
may
infect
peopl
control
essenti
global
medic
commun
remain
inform
vigil
critic
care
team
work
patient
evacu
resourc
rich
set
current
epidem
must
share
best
practic
soon
possibl
regard
organ
dysfunct
beech
et
al
articl
explain
pathogenesi
evd
show
similar
differ
caus
viral
haemorrhag
fever
bacteri
sepsi
systemat
prospect
observ
studi
essenti
clarifi
pathogenesi
pathophysiolog
diseas
human
inform
develop
evid
base
clinic
score
system
manag
algorithm
well
evalu
novel
therapeut
agent
improv
access
basic
support
care
essenti
role
possibl
benefit
aggress
critic
care
intervent
continu
debat
deep
troubl
unwant
effect
sedat
support
year
notabl
submiss
includ
novel
review
larg
dataset
random
control
trial
stateoftheart
new
articl
howev
arguabl
compel
piec
paediatr
intens
care
literatur
icm
simpl
profound
recollect
month
spent
paediatr
intens
care
unit
coma
alarm
dream
written
remark
young
man
describ
recoveri
gunshot
wound
head
piec
provid
uncomfort
insight
patient
experi
may
hardli
notic
monitor
alarm
form
soundtrack
work
live
patient
experi
may
complet
opposit
dream
nightmar
hallucin
dr
emeriaud
colleagu
montreal
highlight
anoth
problem
paediatr
critic
ill
easili
overlook
perform
repeat
estim
maxim
inspiratori
diaphragmat
electr
activ
eadimax
ventil
children
first
systemat
descript
natur
histori
paramet
provid
number
insight
frequent
period
littl
detect
diaphragmat
activ
mechan
ventil
valu
seen
full
ventil
much
lower
preextub
spontan
breath
patient
intub
mainli
lung
patholog
exhibit
higher
eadi
p
patient
support
reason
author
add
emerg
view
may
oversed
oversupport
mani
patient
possibl
use
eadi
proxi
endpoint
clinic
trial
biomark
guid
mechan
ventil
intrigu
manag
ventil
pediatr
acut
respiratori
distress
syndrom
kneyber
jouvert
rimensburg
return
theme
limit
current
practic
need
recogn
potenti
harm
might
caus
present
candid
view
mani
gap
knowledg
new
berlin
definit
suffici
select
patient
random
trial
appropri
infer
guidanc
adult
studi
mlskg
tidal
volum
realli
repres
best
guess
safe
effect
ventil
acut
recoveri
phase
lung
injuri
gener
clinic
meaning
guidanc
bedsid
tool
transpulmonari
pressur
tpp
measur
electr
imped
tomographi
eit
perhap
pressingli
mani
paediatr
intensivist
treasur
use
high
frequenc
oscil
paediatr
ard
limit
evid
sure
need
clinic
trial
data
face
result
oscil
oscar
trial
challeng
provid
data
systematis
sedat
wean
polici
dr
maclaren
brown
thiagarajan
gave
us
view
new
pediatr
ecmo
four
contin
overal
surviv
ecmo
improv
therefor
indic
start
consid
bridg
lung
transplant
anyon
highlight
specif
area
concern
includ
need
inform
advantag
specif
pump
anticoagul
regimen
clear
need
longterm
follow
recent
report
high
rate
late
death
cardiac
ecmo
make
point
starkli
hypoplast
left
heart
syndrom
case
receiv
ecmo
aliv
year
later
impact
famili
high
rate
posttraumat
stress
import
neurolog
complic
valu
neurodevelop
followup
highlight
journal
note
end
spectrum
sever
respiratori
failur
publish
import
studi
kremlinbicetr
hospit
pari
document
associ
chang
practic
predominantli
invas
ventil
predominantli
nasopharyng
cpap
support
infant
bronchiol
author
readili
acknowledg
account
potenti
confound
might
aris
chang
practic
case
mix
said
number
case
observ
n
size
effect
invas
ventil
fall
year
associ
signific
reduct
length
stay
cost
mean
ignor
data
increas
option
environ
noninvas
ventil
may
use
highlight
dr
schlapbach
colleagu
brisban
australia
highflow
nasal
cannula
increasingli
use
predominantli
aeromed
transport
median
distanc
km
avail
hfnc
associ
reduc
need
intub
adjust
score
age
presenc
respiratori
diseas
chang
case
mix
receiv
brisban
limit
interpret
data
form
part
steadi
trend
toward
increas
use
noninvas
support
special
review
argent
biban
ask
new
niv
picu
everyon
respiratori
failur
requir
endotrach
intub
piec
highlight
publish
randomis
studi
prospect
cohort
studi
repres
best
data
niv
paediatr
critic
ill
current
avail
one
problem
around
gener
evid
varieti
techniqu
trigger
mechan
patient
interfac
well
option
patient
select
time
combin
make
good
research
area
difficult
howev
excus
attempt
argent
biban
put
clearli
noninvas
techniqu
potenti
substanti
improv
safeti
ventil
support
children
improv
access
ventilatori
support
acut
chronic
condit
given
respiratori
problem
among
import
caus
childhood
death
across
world
behov
us
explor
potenti
collect
data
research
paediatr
airway
strong
theme
year
icm
dr
wakeham
colleagu
use
virtual
paediatr
intens
care
databas
document
wide
variabl
practic
around
tracheostomi
use
north
american
paediatr
intens
care
unit
admiss
underw
tracheostomi
median
length
stay
day
interquartil
rang
day
tracheostomi
rate
amongst
larger
contributor
studi
vari
author
right
suggest
differ
unlik
attribut
case
mix
differ
alon
set
paediatr
intensivist
seriou
challeng
remov
unhelp
variabl
practic
dr
baranw
colleagu
made
valuabl
contribut
anoth
unknown
paediatr
airway
manag
ask
dexamethason
pretreat
superior
pretreat
prevent
postextub
airway
obstruct
children
recruit
children
age
month
year
eleg
random
doubleblind
trial
two
group
similar
baselin
longer
h
pretreat
significantli
reduc
incid
h
pretreat
vs
h
p
rel
risk
ci
durat
postextub
airway
obstruct
assess
modifi
croup
score
longer
pretreat
halv
reintub
rate
ci
studi
power
detect
differ
rel
rare
event
reintub
took
place
studi
implic
data
clear
sinc
pretreat
h
might
mean
delay
extub
scenario
princ
et
al
london
examin
associ
weightforag
case
mix
adjust
outcom
critic
ill
children
addit
size
dataset
strength
comparison
healthi
refer
popul
unit
kingdom
surprisingli
critic
ill
children
lower
weightforag
healthli
peer
studi
confirm
find
amongst
adult
smaller
paediatr
studi
children
weightforag
popul
mean
significantli
better
casemix
adjust
surviv
similar
obes
paradox
observ
adult
sepsi
inde
associ
weightforag
standardis
mortal
ratio
follow
ushap
distribut
mani
thing
intens
care
accompani
editori
nadel
argent
point
much
inform
need
understand
nutrit
need
patient
zinter
et
al
describ
outcom
paediatr
cancer
emerg
admiss
admiss
us
virtual
picu
system
databas
diagnosi
leukaemia
lymphoma
outsid
first
induct
still
carri
highrisk
tariff
paediatr
index
mortal
score
system
icu
admiss
thing
may
chang
overal
surviv
paediatr
cancer
continu
improv
year
surviv
paediatr
cancer
patient
make
least
one
visit
icu
larg
seri
observ
icu
mortal
cancer
admiss
picu
figur
lower
mani
seri
quot
previous
healthi
children
communityacquir
sepsi
acut
respiratori
distress
syndrom
ard
picu
observ
rel
risk
picu
death
cancer
still
highli
signific
ci
truth
reflect
overal
improv
picu
outcom
cancer
lag
behind
acut
myeloid
leukaemia
case
much
wors
outcom
multipl
variant
analysi
strikingli
surviv
ecmo
solid
haematolog
cancer
patient
seenthough
post
hematopoiet
stem
cell
transplant
group
uniformli
badli
summari
character
two
main
theme
mine
larg
dataset
reveal
pattern
care
previous
unawar
observ
highlight
mani
vari
gap
knowledg
conflict
interest
none
